A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

ABSTRACT:

Background

KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclinical studies. This study determined the safety, preliminary clinical activity, and pharmacokinetics of KW-2478, an Hsp90 inhibitor, in combination with BTZ in patients with relapsed/refractory multiple myeloma (MM).

Methods

Phase I dose escalation determined the recommended phase II dose (RP2D) of KW-2478 plus BTZ, which was then used during phase II.

Results

The maximum tolerated dose was not reached during phase I and the RP2D was KW-2478 175 mg m^-2 plus BTZ 1.3 mg m^-2 on days 1, 4, 8, and 11 every 3 weeks. In the efficacy evaluable phase I/I

SUBMITTER: Cavenagh J 

PROVIDER: S-EPMC5672925 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature